Search results
Dr. Heidi Zhang is the Executive Vice President and Head of Technical Operations at Tune Therapeutics. A seasoned scientific executive who has led global teams across a range of biotech and pharma companies, including Juno Therapeutics, Genentech, Novartis, and Amgen. Prior to Tune, Heidi was the Vice President of Cell Therapy Product ...
Jan 19, 2018 · On Jan. 16, 2017, the bioscience market has reacted with enthusiasm from the news that Celgene Corporation (NASDAQ:CELG) is in discussion to acquire Juno Therapeutics (NASDAQ:JUNO).
May 12, 2018 · A high-level overview of Juno Therapeutics (JUNO) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools.
Jan 10, 2019 · Things are a little on edge in Seattle's biotech scene after the Jan. 3 announcement that pharmaceutical giant Bristol-Myers Squibb (BMS) intends to buy Celgene, the parent company of Juno ...
Sep 28, 2022 · The results of this study of a GPRC5D-targeted CAR T-cell therapy (MCARH109) confirm that GPRC5D is an active immunotherapeutic target in multiple myeloma. (Funded by Juno Therapeutics/Bristol ...
Aug 26, 2021 · JUNO THERAPEUTICS, INC. v. KITE PHARMA, INC. 5 binds the CD19 antigen, a -zeta CD3chain portion, and a costimulatory signaling region. J.A. 58; see also Kite Br. 11; J.A. 383–96 (Complaint). Juno sued Kite, alleging infringem ent of various claims of the ’190 patent through the use, sale, offer for sale, or importation of YESCARTA ®
Recently, Juno Therapeutics embarked on a project to combine their multiple locations into one headquarter location. Juno and Flad Architects engaged Studio Other and Tangram Technology for custom workspace and technology integration throughout the nine floors of Juno’s new 195,000-square-foot offices.
